Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Chugai Pharmaceutical Co. Stories

2013-11-12 00:21:56

LUGANO, Switzerland, November 12, 2013 /PRNewswire/ -- Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their...

2013-05-15 12:33:06

PENZBERG, Germany, May 15, 2013 /PRNewswire/ -- Researchers from academia throughout Europe are invited to participate In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO, ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to submit abstracts which describe their scientific work in the field of tumor-selective membrane targets for antibody-based cancer therapy. The award aims to honor and support outstanding research in the...

2013-01-17 12:27:20

INDIANAPOLIS, Jan. 17, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche Diagnostics Corporation has been selected to FORTUNE magazine's annual list of the "100 Best Companies to Work For." Roche debuted at 89 on the list and is the only Indiana-based company selected. (Photo: http://photos.prnewswire.com/prnh/20130117/DE44332 ) "Being named a 'Best Company to Work For' validates what we already know about our organization," said Jack Phillips, president...

2013-01-08 00:20:43

LAUSANNE, Switzerland and TOKYO, January 8, 2013 /PRNewswire/ -- Chugai Pharmaceutical Co., Ltd. ("Chugai") and Debiopharm GroupTM ("Debiopharm") announced today that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology. Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialise FF284...

2012-11-14 12:26:24

INDIANAPOLIS, Nov. 14, 2012 /PRNewswire/ -- Mayor Greg Ballard today joined Roche Diagnostics President and CEO Jack Phillips as well as other Roche executives and community leaders to break ground on the company's new Learning and Development Center. The center is the first element of a $300 million site transformation investment that was announced in June 2012. The city of Indianapolis and the Indiana Economic Development Corporation offered Roche tax abatements, tax credits and training...

2012-11-12 16:24:22

INDIANAPOLIS, Nov. 12, 2012 /PRNewswire/ -- Roche Diagnostics, a world leader in pharmaceuticals and diagnostics, announced in June its plans to invest $300 million during the next 10 years in expanding its North American headquarters located on the northeast side of Indianapolis. The first phase of the project is a new Learning and Development Center, where approximately 1,500 customers from across the nation will be trained each year. Mayor Greg Ballard will be joined by Roche...

2012-07-31 02:27:49

PENZBERG, Germany, July 31, 2012 /PRNewswire/ -- Roche and SynenTec today announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optimal support and development of the technology for its customers. The Cellavista Imaging System for noninvasively measuring cell...

2012-07-25 10:23:32

INDIANAPOLIS, July 25, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated vitamin D test for use on cobas® modular platforms, further expanding the company's bone metabolism test menu. Vitamin D is an important building block for human health and is mainly produced in the skin by exposure to sunlight. Vitamin D deficiency plays a major role in bone metabolism...

2012-06-27 06:25:40

INDIANAPOLIS, June 27, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch in the U.S. and Canada of the cobas p 312 pre-analytical system, a front-end automation solution that offers comprehensive, vendor-neutral sample management for labs with limited floor space. The compact, stand-alone system performs sample registration, sorting, decapping and archiving of all sample tubes--including chemistry, immunoassay, hematology, coagulation and urinalysis--for the...

2012-03-28 02:24:53

PENZBERG, Germany, March 28, 2012 /PRNewswire/ -- Roche's xCELLigence RTCA [https://www.roche-applied-science.com/sis/xcelligence/index.jsp?&id=xcect_000000 ] System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016. As of 2013, animal experiments are no longer permitted for use in toxicology testing in the cosmetic industry. Significant progress has been made in recent years...